CA2880682A1 - Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one - Google Patents

Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one Download PDF

Info

Publication number
CA2880682A1
CA2880682A1 CA2880682A CA2880682A CA2880682A1 CA 2880682 A1 CA2880682 A1 CA 2880682A1 CA 2880682 A CA2880682 A CA 2880682A CA 2880682 A CA2880682 A CA 2880682A CA 2880682 A1 CA2880682 A1 CA 2880682A1
Authority
CA
Canada
Prior art keywords
pyrazino
dihydro
methyl
indol
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2880682A
Other languages
English (en)
French (fr)
Inventor
Simona M. Ceccarelli
Ravi Jagasia
Roland Jakob-Roetne
Juergen Wichmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2880682A1 publication Critical patent/CA2880682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
CA2880682A 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one Abandoned CA2880682A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12179381 2012-08-06
EP12179381.4 2012-08-06
PCT/EP2013/066344 WO2014023674A1 (en) 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

Publications (1)

Publication Number Publication Date
CA2880682A1 true CA2880682A1 (en) 2014-02-13

Family

ID=48918402

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2880682A Abandoned CA2880682A1 (en) 2012-08-06 2013-08-05 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

Country Status (24)

Country Link
US (1) US9284321B2 (enExample)
EP (1) EP2880036B1 (enExample)
JP (1) JP5974177B2 (enExample)
KR (1) KR101716062B1 (enExample)
CN (1) CN104540829B (enExample)
AR (1) AR092041A1 (enExample)
AU (1) AU2013301577B2 (enExample)
BR (1) BR112015000313A2 (enExample)
CA (1) CA2880682A1 (enExample)
CL (1) CL2015000143A1 (enExample)
CO (1) CO7141435A2 (enExample)
CR (1) CR20140545A (enExample)
EA (1) EA025884B1 (enExample)
IL (1) IL236808B (enExample)
MA (1) MA37791B1 (enExample)
MX (1) MX362184B (enExample)
MY (1) MY185216A (enExample)
NZ (1) NZ703192A (enExample)
PE (1) PE20150341A1 (enExample)
PH (1) PH12015500059B1 (enExample)
SG (1) SG11201408529VA (enExample)
TW (1) TWI506027B (enExample)
UA (1) UA113013C2 (enExample)
WO (1) WO2014023674A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913335T3 (es) * 2013-02-18 2022-06-01 Labrador Diagnostics Llc Análisis de imagen y medición de muestras biológicas
MX2015013915A (es) * 2013-04-02 2015-12-11 Hoffmann La Roche Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.
RU2673489C2 (ru) * 2013-09-12 2018-11-27 Ф. Хоффманн-Ля Рош Аг Производные индолкарбоксамида

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965981C3 (de) * 1968-02-13 1978-08-31 Sumitomo Chemical Co., Ltd., Osaka (Japan) 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
ATE448230T1 (de) * 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
MX2009004898A (es) * 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
MX2015013915A (es) * 2013-04-02 2015-12-11 Hoffmann La Roche Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona.

Also Published As

Publication number Publication date
TW201410679A (zh) 2014-03-16
EP2880036B1 (en) 2017-03-08
EP2880036A1 (en) 2015-06-10
NZ703192A (en) 2016-04-29
JP2015524456A (ja) 2015-08-24
MX362184B (es) 2019-01-08
CL2015000143A1 (es) 2015-06-19
AU2013301577A1 (en) 2014-12-18
EA201590125A1 (ru) 2015-05-29
MX2015001318A (es) 2015-04-17
CO7141435A2 (es) 2014-12-12
TWI506027B (zh) 2015-11-01
US20150246922A1 (en) 2015-09-03
AR092041A1 (es) 2015-03-18
AU2013301577B2 (en) 2017-03-30
MY185216A (en) 2021-04-30
JP5974177B2 (ja) 2016-08-23
BR112015000313A2 (pt) 2017-06-27
MA37791A1 (fr) 2016-05-31
EA025884B1 (ru) 2017-02-28
PH12015500059A1 (en) 2015-03-02
CN104540829A (zh) 2015-04-22
PE20150341A1 (es) 2015-02-28
CN104540829B (zh) 2017-04-26
IL236808B (en) 2018-05-31
CR20140545A (es) 2015-01-12
UA113013C2 (uk) 2016-11-25
SG11201408529VA (en) 2015-01-29
KR20150027832A (ko) 2015-03-12
WO2014023674A1 (en) 2014-02-13
KR101716062B1 (ko) 2017-03-13
HK1206355A1 (en) 2016-01-08
US9284321B2 (en) 2016-03-15
MA37791B1 (fr) 2016-12-30
PH12015500059B1 (en) 2015-03-02

Similar Documents

Publication Publication Date Title
US12319703B2 (en) Macrocyclic fused pyrazoles as Mcl-1 inhibitors
TWI749404B (zh) 作為mcl-1抑制劑的大環吲哚
ES2780699T3 (es) Amidas de piperidina fusionadas útiles como moduladores de canales iónicos
AU2019237992B2 (en) Oxadiazole transient receptor potential channel inhibitors
TWI572607B (zh) 溴區域抑制劑及其用途
CA2994478C (en) Substituted benzimidazoles, their preparation and their use as pharmaceuticals
TW201144322A (en) Spiro-tetracyclic ring compounds as Beta-secretase modulators and methods of use
US20150259308A1 (en) Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
RS64321B1 (sr) Fuzionisani pirolini koji se ponašaju kao inhibitori ubikvitin specifične proteaze 30 (usp30)
TW201139449A (en) Sulfonamide derivatives as MEK inhibitors
JP2020519667A (ja) ＬＳＤ−１インヒビターとしてのピロロ〔２，３−ｃ〕ピリジン及び関連類似体
KR20090107068A (ko) 헤테로시클리덴-ｎ-(아릴)아세트아미드 유도체
WO2012071279A1 (en) Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
JP2014526560A (ja) β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
JP2021513519A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
CA3210553A1 (en) Bicyclic tetrahydroazepine derivatives for the treatment of cancer
US20240199613A1 (en) Polycyclic inhibitors of plasma kallikrein
CA2825906A1 (en) Compounds for the reduction of .beta.-amyloid production
EP4596554A1 (en) Aza-fused ring compound, preparation method therefor, and use thereof in medicine
CA2880682A1 (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
TW202126636A (zh) 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
WO2025011479A1 (en) Pyrazole based inhibitors of LDH and their use in immune and inflammatory diseases
NZ716609B2 (en) Fused piperidine amides as modulators of ion channels

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180712

FZDE Discontinued

Effective date: 20200831